WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · HB 5147

Legislative bill overview

HB 5147 establishes a regulatory framework in Texas allowing patients access to investigational stem cell treatments outside of standard FDA clinical trial processes. The bill creates pathways for physicians to administer experimental stem cell therapies to patients who have exhausted conventional treatment options, subject to specified safety and informed consent requirements.

Why is this important

This legislation directly affects Texas patients with serious or terminal conditions by potentially expanding treatment options, while also raising questions about medical oversight, safety standards, and liability. The bill reflects a broader national tension between patient autonomy/access and rigorous medical evidence requirements that protect public health.

Potential points of contention

  • Safety and efficacy standards: Allowing treatments outside FDA oversight may bypass rigorous clinical validation, creating risks of ineffective or harmful treatments being administered
  • Patient vulnerability: Terminally ill or desperate patients may pursue unproven therapies with false hope, raising concerns about informed consent and exploitation
  • Medical liability and malpractice: Unclear liability frameworks could expose physicians to legal risk or conversely shield them from accountability for adverse outcomes
  • Interstate regulatory conflicts: Texas authorization of treatments FDA has not approved could create jurisdictional confusion and undermine federal drug safety authority

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.